Daniel Schreiber

Mr. Daniel Schreiber

Institute of Cell Genetics, Medical University of Innsbruck, Innsbruck, Tirol, Austria
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Nature Communications
Verified
Journal Article
Open access
DHDominik Humer
Dominik Humer
VKVictoria Klepsch
Victoria Klepsch
DRDietmar Rieder
Dietmar Rieder
IHIsabel Hölzl
Isabel Hölzl
DSDaniel Schreiber
Daniel Schreiber
GBGottfried Baier
Gottfried Baier
CAR-T cell therapy is effective in hematologic malignancies but remains challenging in solid tumors owing to antigen heterogeneity and tumor microenvironment-induced exhaustion. Here, gene editing of the nuclear receptor NR2F6 restores CAR-T cell functionality, sustaining a TCF1⁺ progenitor-exhausted phenotype, enhancing metabolic fitness, and preserving cytotoxic potency under chronic antigen exposure. In immunocompetent models, Nr2f6-deficient CAR-T cells suppress solid tumor growth and induce robust, polyclonal host antitumor responses that persist after CAR-T clearance, as demonstrated by tumor re-challenge protection. Although infused CAR-T cells disappear within 2 weeks, durable tumor control coincides with epitope spreading and secondary immune responses, likely via dendritic cell reactivation. Protection against antigen-negative tumors and transferable immunity reveal a dual mode of direct cytotoxicity followed by durable immune reprogramming. This broadened host immunity may offset immune escape driven by antigen heterogeneity or loss, establishing NR2F6 inhibition as a promising CAR-T engineering strategy for durable, antigen-agnostic solid-tumor immunotherapy.

3 August 2026 in Cells
Verified
Journal Article
Open access
PDF file
DSDaniel Schreiber
Daniel Schreiber
SPSebastian Peer
Sebastian Peer
CLChristina Lutz-Nicoladoni
Christina Lutz-Nicoladoni
JKJiří Koutník
Jiří Koutník
VLViktor Lang
Viktor Lang
GBGottfried Baier
Gottfried Baier
CBL-B is an intracellular E3 ubiquitin ligase that acts as a T cell checkpoint by raising activation thresholds and limiting effector function. Here, genetic targeting of CBL-B enhances the performance of adoptively transferred T cells and CAR T cells under tumor microenvironment-like stress. In fully immunocompetent mouse models, Cblb deficiency or transient Cblb silencing improves control of MC-38 colon carcinoma and autochthonous mammary tumors, demonstrating that CBL-B restrains anti-tumor immunity. Cblb-deficient T cells show enhanced expansion and effector/effector-memory differentiation during an in vivo mixed lymphocyte reaction, confirming a cell-intrinsic brake function of CBL-B during sustained antigenic challenge. In a syngeneic Panc02-EpCAM model, Cblb-deficient anti-EpCAM CAR T cells show superior tumor control, enhanced infiltration, prolonged survival, and preserved effector function despite chronic antigen exposure and TGF-β. Mechanistically, Cblb targeting maintains granzyme B and IFN-γ production and is associated in vitro with increased GSDME-linked pyroptotic tumor cell death, consistent with features of immunogenic cell death. These findings extend previous CBL-B CAR T work from lymphocyte-deficient to immunocompetent settings and support CBL-B inhibition as a strategy to engineer CAR T cells that resist suppressive tumor microenvironments while promoting a more inflammatory mode of tumor killing.

26 October 2026 in iScience
Verified
Journal Article
Open access
JKJiří Koutník
Jiří Koutník
TGThomas Gruber
Thomas Gruber
DFDorothee Freimark
Dorothee Freimark
DHDominik Humer
Dominik Humer
DSDaniel Schreiber
Daniel Schreiber
GBGottfried Baier
Gottfried Baier